X

Saamya Biotech (India) Ltd Stock Analysis

Small Cap
Evaluated by 105 users | BSE: 532905 | NSE: |
Pharmaceuticals & Drugs
Saamya Biotech (India) was incorporated as a public limited company on August 13, 2002 and certificate of commencement of business was issued on August 26, 2002. The promoters of the company are Dr. Y. Manivardhan Reddy and Dr. Y. Sonia Reddy and it is engaged in business of manufacturing,...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Return on Capital Employed 0000.08%0.65%1.19%-1.05%0.42%-2.11%-1.62%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 0002.416.323.1313.428.814.4
Y-o-Y Gr. Rt.-NANANA592.8%41.7%-87.1%348.3%115.3%-50%
Adjusted EPS (Rs.) 0000.010.08-0.07-0.150.05-0.28-0.21
Y-o-Y Gr. Rt.-NANANA700%-187.5%NANA-660%NA
Book Value per Share (Rs.) 9.969.999.991010.0511.9211.7611.811.5311.35
Adjusted Net Profit 00000.2-0.2-0.40.1-0.7-0.5
Net Op. Cash Flow (Rs. Cr.) -1-2.2-3.90.4-0.7-1-0.2-0.20.60.1
Debt to Cash Flow from Ops -0.55-0.45-0.030.41-0.3-0.38-1.8-19.975.8239.53
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Saamya Biotech (India) Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales NA-2.4%69.1%-50%
Adjusted EPS NA-221.3%NANA
Book Value per Share 1.52.5-1.2-1.6
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Return on Equity (%) 0000.070.56-0.54-1.120.41-2.4-1.82
Operating Profit Margin (%) 0001.352.632.54-9.112.490.82-0.9
Net Profit Margin (%) 0000.871.08-0.77-12.580.97-2.42-3.61
Debt to Equity 0.070.040.010.010.010.010.010.150.130.11
Working Capital Days 0002,1591452332,5994803531,146
Cash Conversion Cycle 0001313322423299
Entity Percentage Holding
Promoters 25.62%
Non-Institutions 74.38%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Saamya Biotech (India) was incorporated as a public limited company on August 13, 2002 and certificate of commencement of business was issued on August 26, 2002. The promoters of the company are Dr. Y. Manivardhan Reddy and Dr. Y. Sonia Reddy and it is engaged in business of manufacturing, import, export and dealing in all types of chemicals pharmaceuticals drugs and intermediates.

Saamya Biotech (India) (SBIL) is a new generation biotechnology company incorporated in India (Hyderabad)

Saamya Biotech (India) was incorporated as a public limited company on August 13, 2002 and certificate of commencement of business was issued on August 26, 2002. The promoters of the company are Dr. Y. Manivardhan Reddy and Dr. Y. Sonia Reddy and it is engaged in business of manufacturing, import, export and dealing in all types of chemicals pharmaceuticals drugs and intermediates.

Saamya Biotech (India) (SBIL) is a new generation biotechnology company incorporated in India (Hyderabad) with the aim to manufacture and market biopharmaceuticals and recombinant protein products of medical and industrial importance, and also to discover and develop emerging biotech products of far reaching significance. The company proposes to set up world class facilities for the manufacture of fermentation based high value biotech products. The company embarks on developing effective strategies for the production and supply of both bulk and formulations with special focus on life saving drug entities at affordable price.

The company has entered into technology transfer agreement with Biofin laboratories s.r.l Italy for technology know-how to manufacture bio-pharmaceutical ingredients.

The company entered into sales and purchase agreement with Finchimica, Italy on September 18, 2004, in terms of which Finchimica, Italy would buy all the products manufactured by it to the extent of 100%.

Product range off the company includes:

  • Daunomycin
  • Hyaluronic acid (Pharma grade)
  • Tacrolimus and Rapamycin
  • Cyclosporin A, Probiotics
  • Lysergic acid
  • Mycophenolic acid
  • Clavulenic acid
  • Vancomycin
  • Co-enzyme Q10
  • Interferon β
  • Monoclonal antibodies (anti-cancer).
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback